Get started
Work

LBA27 First-in-human results of STX-478, a mutant-selective PI3Ka inhibitor, in advanced solid tumor patients

Year: 2024
Type: conference-abstract
DOI: 10.1016/j.annonc.2024.08.2266
Authors: A.J. Montero, A. Giordano, K. Jhaveri, P. Munster, J. Rodon, P. Lorusso, D. Orr, J. Bartolomé Arcilla, A. Italiano, A. Elias, A. Soyano, M. De Miguel, B. Doger de Spéville, G. Daniele, J. O'Shaughnessy, T.C. Hernandez Guerrero, R. Wesolowski, C. Saura Manich, M. Chao, D. Juric
Institutions: University Hospitals of Cleveland, Case Western Reserve University, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, University of California, San Francisco, The University of Texas MD Anderson Cancer Center, Yale University, Mary Crowley Cancer Research Center, Hospital Clínico San Carlos, Institut Bergonié, University of Colorado Anschutz, Moffitt Cancer Center, Hospital Universitario HM Sanchinarro, Hospital Universitario Fundación Jiménez Díaz, Agostino Gemelli University Polyclinic, The Ohio State University Wexner Medical Center, The Ohio State University, Vall d'Hebron Institute of Oncology, Scorpion Therapeutics (United States), Harvard University, Massachusetts General Hospital
Language: English
Open Access status: bronze
OpenAlex ID: W4402565463
Cites:
Cited by: 9
Related to: 10